Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

This open-label phase 2 study (CONTRALTO) assessed the safety and efficacy of BCL-2 inhibitor venetoclax (VEN) plus rituximab (R), and VEN plus bendamustine (B) and R, vs B + R (BR) alone in relapsed/refractory (R/R) follicular lymphoma. Patients in the chemotherapy-free arm (arm A: VEN + R) receive...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Zinzani, Pier Luigi, Flinn, Ian W., Yuen, Sam L. S., Topp, Max S., Rusconi, Chiara, Fleury, Isabelle, Le Dû, Katell, Arthur, Christopher, Pro, Barbara, Gritti, Giuseppe, Crump, Michael, Petrich, Adam, Samineni, Divya, Sinha, Arijit, Punnoose, Elizabeth A., Szafer-Glusman, Edith, Spielewoy, Nathalie, Mobasher, Mehrdad, Humphrey, Kathryn, Kornacker, Martin, Hiddemann, Wolfgang
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2020
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7735159/
https://ncbi.nlm.nih.gov/pubmed/32785666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005588
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg